Can a Two-Drug combo stop a rare, aggressive nerve tumor?
NCT ID NCT07743554
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether the combination of avutometinib and defactinib can stop or shrink malignant peripheral nerve sheath tumors (MPNST) that have returned or cannot be removed with surgery. The study enrolls people over 12 years old with relapsed, refractory, metastatic, or unresectable MPNST. The main goal is to see how many participants remain progression-free after four months of treatment, while also assessing safety and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- avutometinib in combination with defactinib
- What this could lead to
- If successful, this combination could offer a new treatment option for people with malignant peripheral nerve sheath tumors that have returned or cannot be surgically removed.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the drugs may not work as hoped or may cause significant side effects. The results will need confirmation in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MPNST (MALIGNANT PERIPHERAL NERVE SHEATH TUMOR) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.